United Therapeutics Corporation: Business Overview, Financials & Competitive Analysis
United Therapeutics Corporation scores 8/10 on the AskCyborg Cyborg Score (Strong). Uniquely positioned biotech leader combining established pulmonary hypertension franchise with transformative organ transplant technology and first-mover advantage in xenotransplantation. United Therapeutics has a market cap of approximately $22.9 billion with a P/E ratio of 19.15. The company combines strong commercial products in rare respiratory diseases with pioneering work in.
What is United Therapeutics Corporation's industry? United Therapeutics Corporation (unither.com) operates in Biotechnology & Specialty Pharmaceuticals. AskCyborg classifies United Therapeutics Corporation under Biotechnology & Specialty Pharmaceuticals in its company registry.
United Therapeutics is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. The company seeks to develop treatments for rare...
Cyborg Score thesis
Uniquely positioned biotech leader combining established pulmonary hypertension franchise with transformative organ transplant...
Read the full analyst-debate transcript →Get the Latest United Therapeutics Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeUnited Therapeutics Corporation Overview
Pro stress-test →United Therapeutics is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. The company seeks to develop treatments for rare, deadly diseases and was founded in 1996 by a family seeking a cure for their daughter's pulmonary arterial hypertension. The firm operates as a public benefit corporation with a dual mission of delivering pharmaceutical therapies and expanding organ transplant availability.
Strategic Profile
Pro stress-test →Many of the company's products are focused towards lung disease and organ manufacturing. Key approved products include Orenitram, Remodulin, Tyvaso, and Tyvaso DPI for pulmonary arterial hypertension, with Tyvaso and Tyvaso DPI also indicated for pulmonary hypertension associated with interstitial lung disease. The pipeline includes gene therapy products like Aurora-GT and development-stage xenografts for organ replacement.
Competitive Landscape
Pro stress-test →Key competitors in the specialty drug manufacturing space include Neurocrine Biosciences (market cap $13.7B), Alkermes (market cap $4.7B), and Kiniksa Pharmaceuticals. United Therapeutics maintains competitive differentiation through its exclusive focus on transplantation and rare lung diseases, combined with proprietary xenotransplantation technology that has limited competition in the organ replacement market.
Industry Context
United Therapeutics Corporation operates in Biotechnology & Specialty Pharmaceuticals.
Key facts
Founded: 1996 · Headquarters: Silver Spring, Maryland · Employees: 1,168 · Revenue: $2.8B · Market cap: $22.9B